| 1.425 0.015 (1.07%) | 10-08 14:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.76 | 1-year : | 1.9 |
| Resists | First : | 1.51 | Second : | 1.62 |
| Pivot price | 1.43 |
|||
| Supports | First : | 1.32 | Second : | 1.09 |
| MAs | MA(5) : | 1.43 |
MA(20) : | 1.44 |
| MA(100) : | 1.41  |
MA(250) : | 1.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37.9 |
D(3) : | 39.3 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 3.76 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACET ] has closed above bottom band by 39.8%. Bollinger Bands are 44.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.49 - 1.5 | 1.5 - 1.51 |
| Low: | 1.36 - 1.37 | 1.37 - 1.38 |
| Close: | 1.4 - 1.41 | 1.41 - 1.42 |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Fri, 04 Oct 2024
Renaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Mon, 30 Sep 2024
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Mon, 30 Sep 2024
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 78.3 (%) |
| Shares Short | 4,180 (K) |
| Shares Short P.Month | 4,570 (K) |
| EPS | -2.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.3 % |
| Return on Equity (ttm) | -58 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|